Dear Dr. Cohen:

Please refer to your Supplemental New Drug Applications (sNDA):

<table>
<thead>
<tr>
<th>Application</th>
<th>Product Name</th>
<th>Submitted on:</th>
<th>Received on:</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 204063/S-003</td>
<td>Tecfidera (dimethyl fumarate)</td>
<td>January 31, 2014</td>
<td>February 3, 2014</td>
</tr>
</tbody>
</table>

This supplement, submitted as a “Prior Approval supplement,” proposes:

- The temporary dose reduction to manage flushing and gastrointestinal side effects associated with Tecfidera treatment.

<table>
<thead>
<tr>
<th>Application</th>
<th>Product Name</th>
<th>Submitted on:</th>
<th>Received on:</th>
</tr>
</thead>
</table>

This supplement, submitted as a “Prior Approval supplement,” proposes changes to:

- Highlights and Section 4: Contraindication for patients with known hypersensitivity to dimethyl fumarate or to any of the excipients of Tecfidera
- Section 5.1: Hypersensitivity reactions (section added)
- Section 8.1: Pregnancy registry phone number updated and website added

<table>
<thead>
<tr>
<th>Application</th>
<th>Product Name</th>
<th>Submitted on:</th>
<th>Received on:</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 204063/S-010</td>
<td>Tecfidera (dimethyl fumarate)</td>
<td>November 6, 2014</td>
<td>November 6, 2014</td>
</tr>
</tbody>
</table>

This supplement, submitted as a “Prior Approval supplement,” proposes changes to:

- Highlights: Warnings and Precautions
- Section 2.1 – Dosing and Administration
- Section 5.2 – Progressive Multifocal Leukoencephalopathy (section added)
- Section 5.3 – Lymphopenia
- Section 17 – Patient Counseling Information
- Patient Information

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.


The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [link]. Information and Instructions for completing the form can be found at [link]. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see [link].

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in these supplements, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Laurie Kelley, PA-C, Regulatory Project Manager, via telephone at (301) 796-5068 or via email at Laurie.Kelley@fda.hhs.gov.

Sincerely,

Billy Dunn, M.D.  
Acting Director  
Division of Neurology Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

Reference ID: 3666921
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

WILLIAM H Dunn
12/03/2014